Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy

Summary

Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.

Eligibility

Inclusion Criteria:

* Female
* Over 18 years old
* Breast cancer
* Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg/m2 of doxorubicin.

Exclusion Criteria:

* Contraindications for performing CMR exams, such as patients with pacemakers or cardiac defibrillators of any type, metal clips for cerebral aneurysms, cochlear implants, and ventriculoperitoneal bypass valves.
* Inability to perform CMR due to claustrophobia.
* Renal failure with a glomerular filtration rate \< 30 ml/min/1.73 m2.
* Previous history of myocardial infarction, congestive heart failure, or myocardial revascularization, whether percutaneous or surgical.
* Previous history of significant valvular heart disease.
* Previous history of cardiomyopathies.

Conditions2

Interventions1

Related trials

• A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record — Herlev and Gentofte Hospital
• A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting) — Boryung Pharmaceutical Co., Ltd
• A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed) — Boryung Pharmaceutical Co., Ltd
• DAPAgliflozin for Renal Protection in Heart Transplant Recipients — Oslo University Hospital
• Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD — Tor Biering-Sørensen
• The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients — University Health Network, Toronto
• Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients — University Medical Centre Ljubljana

Browse More Trials